title: DPCP for the treatment of alopecia areata.
abstract: Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety. Because DPCP has at least a 40% success rate for cosmetically acceptable regrowth in extensive alopecia areata, its availability is an important matter for patients with alopecia areata.
authors.affiliation: Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Bolduc
authors.forename: J
authors.initials: J
authors.lastname: Shapiro
mesh_terms: D000287:Administration, Topical; D000506:Alopecia Areata / Q000188:drug therapy*; D003521:Cyclopropanes / Q000627:therapeutic use*; D006197:Hair / Q000254:growth & development; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
chemical_list: D003521:Cyclopropanes; C029402:diphenylcyclopropenone